Efficacy and Safety of Aldosterone Synthase Inhibitors in Hypertension: A Systematic Review and Meta‐Analysis
Endocrinology Diabetes & Metabolism2025Vol. 8(5), pp. e70094–e70094
Citations Over TimeTop 10% of 2025 papers
Jennifer Goh, Sheza Sohail, Haroon Ayub, Zulfiqar F. Cheema, Nitish Behary Paray, S. B. Adikari, Ahmad Mesmar, Mohammad Atout, Abdul Qazi, Ahmad Aldalqamouni, Bilal Younas, Muhammad A. Rauf, Muhammad Azhar Waheed Khan, Aya Abouayana, Ahmed Eid Ahmed Abouayana, Ali Hasan, Maryam Shahzad, Mushood Ahmed, Raheel Ahmed, Saeed Ahmed
Abstract
ASIs effectively lower SBP and serum aldosterone in adults with hypertension. They appear safe overall but may increase the risk of hyperkalemia.
Related Papers
- → Pathology and gene mutations of aldosterone-producing lesions(2023)8 cited
- → Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males(1998)100 cited
- → Selective aldosterone synthase inhibitors reduce aldosterone formation in vitro and in vivo(2009)23 cited
- → Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: Utility of monkey as a surrogate for human(2015)17 cited
- Relationship of aldosterone synthase gene polymorphism with plasma aldosterone levels of essential hypertension patients(2004)